Volume 15, Issue 3 (5-2017)                   IJRM 2017, 15(3): 169-174 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F, Pourdarvishi F et al . Expression of placental growth factor mRNA in preeclampsia. IJRM. 2017; 15 (3) :169-174
URL: http://journals.ssu.ac.ir/ijrmnew/article-1-804-en.html
1- Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
2- Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran , rajaei_minoo@yahoo.com
3- 1. Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. 2.Department of Medical Genetics; Faculty of Medicine; Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
4- Fertility and Infertility Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Abstract:   (612 Views)
Background: Preeclampsia (PE) is a serious complication of pregnancy withhallmarks of incomplete placentation, placental ischemia and endothelialdysfunction. Imbalance between vascular endothelial growth factor (VEGF),placenta growth factor (PlGF) and their receptors play important role inpathophysiology of PE.
Objective: This study was aimed to asses PlGF mRNA expression in placenta ofwomen affected with PE.
Material and Methods: In this cross-sectional study, expression of PlGF mRNAwas evaluated in 26 mild PE cases, 15 severe preeclamptic women and 20normotensive controls. Patients were sub-classified as early onset PE (9) and lateonset (32). After RNA extraction, PlGF expression was quantified with qRT-PCR.
Results: The results of PlGF mRNA expression between mild-severe, and early-lateonset PE patients showed no statistically significant difference compared with thecontrol group (p=0.661, p=0.205 respectively).
Conclusion: Despite we found no distinct differential expression of PlGF mRNA inplacental tissue of PE patients compared with control women, but according todecreased level of this angiogenic factor in PE even before clinical onset of thedisease, determining molecular mechanisms related to reduced secretion of PlGFinto the maternal circulation may be useful for future therapeutics.
Full-Text [PDF 445 kb]   (171 Downloads) |   |   Full-Text (HTML)  (46 Views)  
Type of Study: Original Article |

References
1. Nishizawa H, Ota S, Suzuki M, Kato T, Sekiya T, Kurahashi H, et al. Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol 2011; 9: 107. [DOI:10.1186/1477-7827-9-107]
2. Perucci LO, Gomes KB, Freitas LG, Godoi LC, Alpoim PN, Pinheiro MB, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PloS One 2014; 9: e97632. [DOI:10.1371/journal.pone.0097632]
3. Kaitu'u-Lino T, Hastie R, Cannon P, Nguyen H, Lee S, Hannan N, et al. Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14. Placenta 2015; 36: 932-937. [DOI:10.1016/j.placenta.2015.06.007]
4. Karimi S, Yavarian M, Azinfar A, Rajaei M, Azizi Kootenaee M. Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population. Iran J Reprod Med 2012; 10: 59-66.
5. Wu P, van den Berg C, Alfirevic Z, O'Brien S, Röthlisberger M, Baker PN, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci 2015; 16: 23035-23056. [DOI:10.3390/ijms160923035]
6. Chung J-Y, Song Y, Wang Y, Magness RR, Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2004; 89: 2484-2490. [DOI:10.1210/jc.2003-031580]
7. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-775. [DOI:10.1210/jc.2003-031244]
8. Tsatsaris V, Goffin F, Munaut C, Brichant J-F, Pignon M-R, Noel A, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563. [DOI:10.1210/jc.2003-030528]
9. Kar M. Role of biomarkers in early detection of preeclampsia. J Clin Diagn Res 2014; 8: BE01-4. [DOI:10.7860/JCDR/2014/7969.4261]
10. Tripathi R, Rath G, Jain A, Salhan S. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. Annal Anat Anat Anzeiger 2008; 190: 477-489. [DOI:10.1016/j.aanat.2008.08.002]
11. Torry DS, Hinrichs M, Torry RJ. Determinants of placental vascularity. Am J Reprod Immunol 2004; 51: 257-268. [DOI:10.1111/j.1600-0897.2004.00154.x]
12. Andraweera P, Dekker G, Laurence J, Roberts C. Placental expression of VEGF family mRNA in adverse pregnancy outcomes. Placenta 2012; 33: 467-472. [DOI:10.1016/j.placenta.2012.02.013]
13. Welch PC, Amankwah KS, Miller P, McAsey ME, Torry DS. Correlations of placental perfusion and PlGF protein expression in early human pregnancy. Am J Obstet Gynecol 2006; 194: 1625-1629. [DOI:10.1016/j.ajog.2006.01.012]
14. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1-9. [DOI:10.3858/emm.2012.44.1.025]
15. Furuya M, Kurasawa K, Nagahama K, Kawachi K, Nozawa A, Takahashi T, et al. Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy 2011; 2011: 123717. [DOI:10.1155/2011/123717]
16. Tayade C, Hilchie D, He H, Fang Y, Moons L, Carmeliet P, et al. Genetic deletion of placenta growth factor in mice alters uterine NK cells. J Immunol 2007; 178: 4267-475. [DOI:10.4049/jimmunol.178.7.4267]
17. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125: 911-919. [DOI:10.1161/CIRCULATIONAHA.111.054361]
18. Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. New Eng J Med 2004; 350: 672-683. [DOI:10.1056/NEJMoa031884]
19. Lu F, Longo M, Tamayo E, Maner W, Al-Hendy A, Anderson GD, et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 2007; 196: 396. e1-e7.
20. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658. [DOI:10.1172/JCI17189]
21. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183: 1554-1557. [DOI:10.1067/mob.2000.108022]
22. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonat Med 2008; 21: 9-23. [DOI:10.1080/14767050701830480]
23. Practice ACoO. Practice bulletin# 33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002; 99: 159-167.
24. Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early-vs. late-onset preeclampsia and HELLP syndrome. J Perinatal Med 2013; 41: 511-516. [DOI:10.1515/jpm-2012-0248]
25. Louwen F, Muschol-Steinmetz C, Reinhard J, Reitter A, Yuan J. A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget 2012; 3: 759-773. [DOI:10.18632/oncotarget.595]
26. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003; 101: 1266-1274.
27. Schmidt M, Dogan C, Birdir C, Kuhn U, Gellhaus A, Kimmig R, et al. Placental growth factor: a predictive marker for preeclampsia? Gynäkologisch-geburtshilfliche Rundschau 2009; 49: 94-99. [DOI:10.1159/000197908]
28. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005; 90: 4895-4903. [DOI:10.1210/jc.2004-1955]
29. Maebayashi A, Yamamoto T, Azuma H, Kato E, Kuno S, Murase T, et al. PP121. Expression of PlGF, sFlt, MTF-1, HO-1 and HIF-1 alpha mRNAs in preeclampsia placenta and effect of preeclampsia sera on their expression of choriocarcinoma cells. Pregnancy Hypertens 2012; 2: 304-305. [DOI:10.1016/j.preghy.2012.04.232]
30. Toft JH, Toft JH, Lian IA, Tarca AL, Erez O, Espinoza J, et al. Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PlGF) in placentas from pre-eclamptic and small-for-gestational-age pregnancies. J Matern Fetal Neonat Med 2008; 21: 267-273. [DOI:10.1080/14767050801924118]
31. Pramatirta AY, Mose J, Effendi JS, Krisnadi SR, Anwar AD, Fauziah PN, et al. Correlation between cell-free mRNA expressions and PLGF protein level in severe preeclampsia. BMC Res Notes 2015; 8: 208. [DOI:10.1186/s13104-015-1186-9]
32. Purwosunu Y, Sekizawa A, Yoshimura S, Farina A, Wibowo N, Nakamura M, et al. Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. Reprod Sci 2009; 16: 857-864. [DOI:10.1177/1933719109336622]
33. Hongling S, Hongyu L, Hanping C, Yuzhen G, Ming Z, Xiaoyan X, et al. Analysis of placental growth factor in placentas of normal pregnant women and women with hypertensive disorders of pregnancy. J Huazhong Univ Sci Technol 2006; 26: 116-119. [DOI:10.1007/BF02828055]
34. Semczuk M, Borczynska A, Bialas M, Rozwadowska N, Semczuk-Sikora A, Malcher A, et al. Expression of genes coding for proangiogenic factors and their receptors in human placenta complicated by preeclampsia and intrauterine growth restriction. Reprod Biol 2013; 13: 133-138 [DOI:10.1016/j.repbio.2013.03.004]

Send email to the article author


© 2020 All Rights Reserved | International Journal of Reproductive BioMedicine

Designed & Developed by : Yektaweb